Induction of cuproptosis enhances sensitivity and overcomes resistance to osimertinib in lung cancer

Drug resistance remains the most formidable challenge in lung cancer targeted therapy. Cuproptosis, a novel form of copper-dependent regulated cell death, 1 , 2 has shown promise in overcoming radioresistance, 3 but its potential in targeted therapy remains unexplored.